Por favor, use este identificador para citar o enlazar a este item:
http://hdl.handle.net/10261/349895
COMPARTIR / EXPORTAR:
SHARE CORE BASE | |
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE | |
Título: | Clinical and patient-reported outcome profile of patients with hepatitis B viral infection from the Global Liver Registry™ |
Autor: | Younossi, Zobair M.; Yu, Ming-Lung; Yilmaz, Yusuf; Alswat, Khalid; Buti, Maria; Castellanos Fernandez, Marlen Ivon; Papatheodoridis, Georgios; Hamid, Saeed S.; El-Kassas, Mohamed; Chan, Wah-Kheong; Duseja, Ajay K.; Gordon, Stuart C.; Eguchi, Yuichiro; Isakov, Vasily A.; Roberts, Stuart K.; Fan, Jian-Gao; Singal, Ashwani K.; Romero-Gómez, Manuel CSIC ORCID CVN; Ahmed, Aijaz; Ong, Janus; Lam, Brian P.; Younossi, Issah; Nader, Fatema; Racila, Andrei; Stepanova, Maria; Alqahtani, Saleh | Palabras clave: | Emotional well-being Fatigue Fatty liver Physical functioning Viral hepatitis Work productivity |
Fecha de publicación: | abr-2023 | Editor: | John Wiley & Sons | Citación: | Journal of Viral Hepatitis 30(4): 335-344 (2023) | Resumen: | Chronic hepatitis B (CHB) infection is one of the most common causes of cirrhosis and liver cancer worldwide. Our aim was to assess clinical and patient-reported outcome (PRO) profile of CHB patients from different regions of the world using the Global Liver Registry. The CHB patients seen in real-world practices are being enrolled in the Global Liver Registry. Clinical and PRO (FACIT-F, CLDQ, WPAI) data were collected and compared to baseline data from CHB controls from clinical trials. The study included 1818 HBV subjects (48 ± 13 years, 58% male, 14% advanced fibrosis, 7% cirrhosis) from 15 countries in 6/7 Global Burden of Disease super-regions. The rates of advanced fibrosis varied (3–24%). The lowest PRO scores across multiple domains were in HBV subjects from the Middle East/North Africa (MENA), the highest – Southeast/East and South Asia. Subjects with advanced fibrosis had PRO impairment in 3 CLDQ domains, Activity of WPAI (p < 0.05). HBV subjects with superimposed fatty liver had more PRO impairments. In multivariate analysis adjusted for location, predictors of PRO impairment in CHB included female sex, advanced fibrosis, and non-hepatic comorbidities (p < 0.05). In comparison to Global Liver Registry patients, 242 controls from clinical trials had better PRO scores (Abdominal, Emotional, and Systemic scores of CLDQ, all domains of WPAI) (p < 0.05). In multivariate analysis with adjustment for location and clinicodemographic parameters, the associations of PROs with the enrollment setting (real-life Global Liver Registry vs. clinical trials) were no longer significant (all p > 0.10). The clinico-demographic portrait of CHB patients varies across regions of the world and enrollment settings. Advanced fibrosis and non-hepatic comorbidities are independently associated with PRO impairment in CHB patients. | Versión del editor: | https://doi.org/10.1111/jvh.13800 | URI: | http://hdl.handle.net/10261/349895 | DOI: | 10.1111/jvh.13800 | ISSN: | 1352-0504 | E-ISSN: | 1365-2893 |
Aparece en las colecciones: | (IBIS) Artículos |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
accesoRestringido.pdf | 59,24 kB | Adobe PDF | Visualizar/Abrir |
CORE Recommender
SCOPUSTM
Citations
2
checked on 09-abr-2024
Page view(s)
16
checked on 27-abr-2024
Download(s)
6
checked on 27-abr-2024
Google ScholarTM
Check
Altmetric
Altmetric
NOTA: Los ítems de Digital.CSIC están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.